According to Nova one advisor, the global Retinal Vein Occlusion market was valued at USD 18.2 billion in 2021 and it is expected to hit around USD 34.7 billion by 2030 with a CAGR of 8.4% during the forecast period 2022 to 2030.
According to Nova one advisor, the global Retinal Vein Occlusion market was valued at USD 18.2 billion in 2021 and it is expected to hit around USD 34.7 billion by 2030 with a CAGR of 8.4% during the forecast period 2022 to 2030.
Request Free Sample of This Report@ https://www.novaoneadvisor.com/report/sample/6001
Growth Factors:
Retinal vein occlusion is the blockage of the retinal vein due to blood clot. Retinal vein occlusion is the second most common cause of visual impairment globally. A blood clot causes a blockage in the vein, which starts draining blood from retina, resulting in swelling and bleeding, affecting the vision of the person. Rise in prevalence of eye diseases globally, increase in the geriatric population, surge in awareness about eye disorders, improved healthcare infrastructure, technological advancements, and upcoming novel treatments are the major drivers of the global retinal vein occlusion market.
North America held major share of the global retinal vein occlusion market in 2020 due to improved healthcare infrastructure, rise in prevalence of eye diseases, advanced technology, and increase in the geriatric population. The retinal vein occlusion market in Asia Pacific is likely to expand at a high CAGR of 9.6% from 2022 to 2030. Increase in incidence of eye diseases in Asia Pacific, especially in China, Singapore, Indonesia, and other countries in Southeast Asia, and rise in healthcare expenditure are expected to fuel the growth of the market in Asia Pacific from 2022 to 2030.
Report Scope of the Retinal Vein Occlusion Market
| Report Coverage | Details |
| Market Size | US$ 34.7 Billion by 2030 |
| Growth Rate | CAGR of 8.4% from 2022 to 2030 |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Type, Treatment Type and Region, |
| Companies Mentioned | Alimera Sciences, Allergan (AbbVie, Inc.), Annexin Pharmaceuticals AB (publ), Bayer AG, Carl Zeiss AG, F. Hoffmann-La Roche Ltd., Iridex Corporation, Lumenis, Nidek Co., Ltd., Novartis AG, Regeneron Pharmaceuticals, Inc., and Topcon Corporation.. |
Full Report is Ready | Quick Buy This Premium Report from Here@ https://www.novaoneadvisor.com/report/checkout/6001
Retinal Vein Occlusion Market: Overview
This report analyzes the current scenario and future prospects of the global retinal vein occlusion market. Retinal vein occlusion is the blockage of the retinal vein due to blood clot. Retinal vein occlusion is the second most common cause of visual impairment globally. A blood clot causes a blockage in the vein, which starts draining blood from retina, resulting in swelling and bleeding, affecting the vision of the person. Rise in prevalence of eye diseases globally, increase in geriatric population, surge in awareness about eye disorders, improved healthcare infrastructure, technological advancements, and upcoming novel treatments are the major drivers of the global retinal vein occlusion market.
The report includes an elaborate executive summary, which provides a snapshot of various segments of the global retinal vein occlusion market. It also provides information and data analysis of the global retinal vein occlusion market about segments based on type, treatment type, and region.
The overview section of the report provides a detailed qualitative analysis of drivers, restraints, and opportunities that affect the global retinal vein occlusion market
The report includes company profiles, which provide information about their business, product portfolios, strategic overview, and competition landscape in the global retinal vein occlusion market
The report on the global retinal vein occlusion market offers market attractiveness analysis of regions and segments
The last section of the report comprises quantitative and qualitative analyses on market share/position of key players operating in the global retinal vein occlusion market. It analyzes key competitive strategies adopted by major industry players, thereby presenting a thorough understanding of the competitive scenario in the global retinal vein occlusion market.
Retinal Vein Occlusion Market: Key Segments
In terms of type, the global retinal vein occlusion market has been bifurcated into central retinal vein occlusion and branch retinal vein occlusion. The central retinal vein occlusion segment dominated the global retinal vein occlusion market in 2020, and the trend is projected to continue during the forecast period.
Based on treatment type, the global retinal vein occlusion market has been classified into anti-VEGF drugs, corticosteroid drugs, pan-retinal photocoagulation therapy, and laser therapy. The anti-VEGF drugs segment held major share of the global retinal vein occlusion market in 2020. Rise in prevalence and incidence of diabetes drives the segment.
Market size and forecast for each of these segments and sub-segments have been provided from 2017 to 2030. The CAGR of respective segment has also been provided from 2022 to 2030, considering 2020 as the base year, and 2017, 2018, and 2019 as historical years.
North America to Dominate Global Market; Asia Pacific to Offer Significant Opportunities
In terms of region, the global retinal vein occlusion market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is anticipated to account for leading share of the global retinal vein occlusion market during the forecast period. The retinal vein occlusion market in Asia Pacific is projected to grow at a rapid pace in the near future. India and China are likely to be lucrative markets for retinal vein occlusion treatment during the forecast period.
Some of the prominent players in the Retinal Vein Occlusion Market include:
Alimera Sciences, Allergan (AbbVie, Inc.), Annexin Pharmaceuticals AB (publ), Bayer AG, Carl Zeiss AG, F. Hoffmann-La Roche Ltd., Iridex Corporation, Lumenis, Nidek Co., Ltd., Novartis AG, Regeneron Pharmaceuticals, Inc., and Topcon Corporation.
Segments Covered in the Report
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2030 and covers subsequent region in its scope:
- Retinal Vein Occlusion Market, by Type
- Central Retinal Vein Occlusion
- Branch Retinal Vein Occlusion
- Retinal Vein Occlusion Market, by Treatment Type
- Anti-VEGF Drugs
- Corticosteroid Drugs
- Pan-retinal Photocoagulation Therapy
- Laser Therapy
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Retinal Vein Occlusion industry analysis from 2022 to 2030 to identify the prevailing Retinal Vein Occlusion industry opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the global Retinal Vein Occlusion industry segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global Retinal Vein Occlusion industry trends, key players, market segments, application areas, and market growth strategies.
Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/6001
You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://www.visionresearchreports.com/
Blog: https://qyresearchmedical.com/